Literature DB >> 10746669

Distinction between dysplasia-associated lesion or mass (DALM) and adenoma in patients with ulcerative colitis.

F Fogt1, S J Urbanski, M E Sanders, E E Furth, R L Zimmerman, J J Deren, A E Noffsinger, A O Vortmeyer, C J Hartmann, R L Odze, C A Brown.   

Abstract

Polyps with epithelial dysplasia in ulcerative colitis (UC) represent either dysplasia-associated lesions or masses (DALMs) or sporadic adenomas. DALMs are frequently associated with associated carcinoma and are an indication for colectomy. Removal of the polyp is treatment of choice for sporadic adenomas. Differentiating between these 2 lesions is not always easy. The goal of this study was to distinguish DALMs from adenomas in patients with UC on a genetic basis. We evaluated genetic alterations in DALMs and compared them with a previously published set of dysplastic polyps in patients with UC that were considered adenomas for the following reasons: (1) polyps were located outside of current active disease; (2) polyps had histological features of sporadic adenomas; and (3) patients displayed a uneventful follow-up after polypectomy (UC-adenomas). In addition, adenomas not associated with UC were studied. Genetic alterations on chromosome 3p were assessed for the markers D3S1766, D3S2409, and D3S2387. LOH with or without microsatellite instability was found in 70%, 37%, and 57% of cases of DALM, respectively. In contrast, UC-adenomas lesions exhibited genetic alterations in 8.3%, 11.7%, and 15.3% for the respective markers. Spontaneous adenomas exhibited genetic alterations in 10.5%, 7.1%, and 0% of cases, which were not significantly different from the UC-adenoma results. These results indicate that UC-adenomas are genetically and biologically similar to sporadic adenomas and that UC-adenomas may biologically represent sporadic adenomas, supporting on a genetic basis the criteria chosen to diagnose adenomas in UC. Genetic markers on chromosome 3p may be useful in the differential diagnosis between DALM and UC-adenomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10746669     DOI: 10.1016/s0046-8177(00)80240-3

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

Review 1.  Dysplasia east and west.

Authors:  R M Genta
Journal:  Curr Gastroenterol Rep       Date:  2000-12

2.  Distal adenomatous polyps are rare in patients with inflammatory bowel disease.

Authors:  A Dixon; P Wurm; A Hart; R Robinson
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

3.  Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis.

Authors:  C J van der Woude; H Moshage; M Homan; J H Kleibeuker; P L M Jansen; H van Dekken
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

4.  Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment.

Authors:  M Vieth; H Behrens; M Stolte
Journal:  Gut       Date:  2006-01-19       Impact factor: 23.059

Review 5.  [Sporadic adenoma and colitis-associated intraepithelial neoplasia: a difficult differential diagnosis].

Authors:  M Vieth; H Behrens; M Stolte
Journal:  Pathologe       Date:  2003-01-21       Impact factor: 1.011

Review 6.  Endoscopic and pathological aspects of colitis-associated dysplasia.

Authors:  Fiona D M van Schaik; G Johan A Offerhaus; Marguerite E I Schipper; Peter D Siersema; Frank P Vleggaar; Bas Oldenburg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-22       Impact factor: 46.802

Review 7.  Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis.

Authors:  Marco Scarpa; Ignazio Castagliuolo; Carlo Castoro; Anna Pozza; Melania Scarpa; Andromachi Kotsafti; Imerio Angriman
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 8.  Techniques for targeting screening in ulcerative colitis.

Authors:  David Paul Hurlstone; Steve Brown
Journal:  Postgrad Med J       Date:  2007-07       Impact factor: 2.401

9.  Mitochondrial DNA mutations in preneoplastic lesions of the gastrointestinal tract: a biomarker for the early detection of cancer.

Authors:  Guoping Sui; Shaoyu Zhou; Jean Wang; Marcia Canto; Edward E Lee; James R Eshleman; Elizabeth A Montgomery; David Sidransky; Joseph A Califano; Anirban Maitra
Journal:  Mol Cancer       Date:  2006-12-13       Impact factor: 27.401

10.  Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer.

Authors:  Chang-ho Ryan Choi; Ana Ignjatovic-Wilson; Alan Askari; Gui Han Lee; Janindra Warusavitarne; Morgan Moorghen; Siwan Thomas-Gibson; Brian P Saunders; Matthew D Rutter; Trevor A Graham; Ailsa L Hart
Journal:  Am J Gastroenterol       Date:  2015-09-29       Impact factor: 10.864

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.